Estudo comparativo de modelos computacionais gerados sobre representações de imagens de coloscopia: tecido de mucosa normal VS tecido de mucosa de pólipo cólico Comparative study of computacional models generated from representations of colonoscopic images: normal mucosal tissues VS mucosal tissues of colic polyp

OBJETIVO: analisar a qualidade preditiva de modelos computacionais para a diferenciação de tecidos cólicos, construídos a partir da representação de Imagens de Coloscopia (IC) como Matrizes de Co-ocorrência (MC). MATERIAIS E MÉTODOS: os modelos foram construídos aplicando técnicas de análise de imagens e de inteligência artificial. Foram utilizadas 67 IC, contendo pólipos, a partir das quais foram extraídas uma imagem da parte de tecido de pólipo e outra de tecido sem pólipo adjacente, totalizando 134 imagens. Para cada imagem, foram construídas MC para diferentes valores do parâmetro distância, D = 1 a 5, e extraídas 11 características de textura. Com essa representação, foram criados cinco modelos computacionais baseados em árvores de decisão. Os modelos foram avaliados utilizando: (a) validação cruzada e (b) tabelas de contingência. RESULTADOS: na análise (a), o modelo de D = 3 apresentou o menor erro médio (22,25% ± 11,85%). Na análise (b), os modelos de D = 1 e 3 apresentaram os melhores valores de precisão. CONCLUSÃO: os valores do parâmetro de distância D = 1 e 3 apresentaram os modelos com as melhores qualidades preditivas. Os resultados mostraram que os modelos construídos apresentaram-se promissores para a construção de sistemas computacionais de suporte à decisão.<br>PURPOSE: to evaluate the predictive quality of computational models to differentiate colic tissues, based on Cooccorrurence Matrices (MC) representation of Coloscopic Images (IC). MATERIALS AND METHODS: image analysis and artificial intelligence methods were employed to construct computational models. Sixty seven IC images, containing polyp, were considered in this work, from which a part containing a polypus and another without it were collected given origin to 134 images. For each one of these, different MC were constructed considering five distance parameters (D = 1 to 5) and the extraction of 11 texture characteristics. With this representation, five computational models were generated based on decision trees. These models were evaluated using two techniques: (a) cross-validation and (b) contingency tables. RESULTS: for the (a) analysis, the model with D = 3 presented the smaller average error (22.25% ± 11.85%). For the (b) analysis, models with D = 1 and 3 presented the best precision values. CONCLUSION: parameters D = 1 and 3 presented models with the best predictive qualities. Results showed that the constructed models were promising to be applied within decision making computational systems

Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

Following publication of the original article [1] the authors identified that the collaborators of the TOCIVID-19 investigators, Italy were only available in the supplementary file. The original article has been updated so that the collaborators are correctly acknowledged. For clarity, all collaborators are listed in this correction article

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P<0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P&lt;0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)